We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO and Virginia G. Piper Cancer Center Announce Enrollment of First Patient in Clinical Trial of TSR-011
Company Plans to Expand Phase 1/2 Clinical Trial of the Anaplastic Lymphoma Kinase (ALK) Inhibitor, TSR-011, to Multiple Clinical Trial Sites
View HTML
Toggle Summary TESARO Announces Third Quarter 2012 Operating Results
Continued Enrollment for the Global Registration Program for Rolapitant Announced Clearance of Investigational New Drug Application for TSR-011 Appointed Robert E. Martell, M.D., Ph.D., as Chief Medical Officer WALTHAM, Mass., Oct. 25, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc.
View HTML
Toggle Summary TESARO to Announce Third Quarter 2012 Financial Results on Thursday, October 25th, 2012
WALTHAM, Mass., Oct. 16, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2012 financial results on Thursday, October 25 th , 2012, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on
View HTML
Toggle Summary TESARO Announces Clearance of Investigational New Drug Application for TSR-011
Company Plans to Proceed With a Phase 1/2 Clinical Study of the Anaplastic Lymphoma Kinase (ALK) Inhibitor TSR-011
View HTML
Toggle Summary TESARO, Inc. to Present at the 2012 Morgan Stanley Global Healthcare Conference
WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 2012 Morgan Stanley Global Healthcare Conference at the Grand Hyatt in
View HTML
Toggle Summary TESARO, Inc. Appoints Robert E. Martell, M.D., Ph.D. as Chief Medical Officer
WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the appointment of Dr. Robert Martell as Chief Medical Officer. Dr. Martell is a practicing medical oncologist at Tufts Medical Center who brings extensive drug development experience to TESARO from both
View HTML
Toggle Summary TESARO, Inc. to Present at Upcoming Conferences
WALTHAM, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced that Lonnie Moulder, Chief Executive Officer, will be presenting at the Robert W. Baird 2012 Healthcare Conference at the New York Palace Hotel in New York on Thursday, September 6, 2012 at 2:00 p.m. EDT.
View HTML
Toggle Summary TESARO Announces Second Quarter 2012 Operating Results
Key Rolapitant Clinical Trial Results Presented at ASCO and MASCC Meetings In-Licensed Niraparib, a Potentially First and Best-in-Class PARP Inhibitor Raised Over $86.8 Million in Gross Proceeds from an Initial Public Offering WALTHAM, Mass., July 26, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc.
View HTML
Toggle Summary TESARO, Inc. Announces Exercise of Underwriters' Over-Allotment Option
WALTHAM, Mass., July 24, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the underwriters of its initial public offering have partially exercised their over-allotment option for the purchase of an additional 430,183 shares of TESARO common stock.
View HTML
Toggle Summary TESARO, Inc. to Announce Second Quarter 2012 Financial Results on Thursday, July 26th, 2012
WALTHAM, Mass., July 19, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2012 financial results on Thursday, July 26 th , 2012, before the open of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on
View HTML